Effect of eplerenone on hypertension-associated renal damage in rats: Potential role of peroxisome proliferator activated receptor gamma(PPAR-γ)

Journal of Physiology and Pharmacology

Volumn 62, Issue 1, 2011, Pages 87-94

  Miana, M ^a   de las Heras, N ^a   Rodriguez, C ^b   Sanz Rosa, D ^c   Martin Fernandez, B ^a   Mezzano, S ^d   Lahera, V ^a   Martinez Gonzalez, J ^b   Cachofeiro, V ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

Aldosterone; Eplerenone; Fibrosis; Hypertension; Inflammation; Kidney; PPAR

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; EPLERENONE; INTERLEUKIN 1BETA; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN LYSINE 6 OXIDASE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE EXPRESSION; HYPERTENSION; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY TUBULE DISORDER; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION;

ANIMALS; BLOOD PRESSURE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINES; DOWN-REGULATION; GENE EXPRESSION; HYPERTENSION; KIDNEY CORTEX; KIDNEY DISEASES; MALE; PPAR GAMMA; PROTEIN-LYSINE 6-OXIDASE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SPIRONOLACTONE; UP-REGULATION;

EID: 79955021142     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Martinez-Maldonado M. Role of hypertension in the progression of chronic renal disease. Nephrol Dial Transplant 2001; 16(Suppl 1): 63-66.
2. Maschio G, Oldrizzi L, Marcantoni C, Rugiu C. Hypertension and progression of renal disease. J Nephrol 2000; 13: 225-227.
3. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-816.
4. Whitworth JA. Progression of renal failure - the role of hypertension. Ann Acad Med Singapore 2005; 34: 8-15.
5. Palatini P, Mormino P, Dorigatti F, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006; 70: 578-584.
6. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74: 196-206.
7. Qi W, Chen X, Poronnik O, Pollock CA. Transforming growth factor beta/connective tissue growth factor axis in the kidney. Int J Biochem Cell Biol 2008; 40: 9-13.
8. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009; 54: 877-884.
9. Rodriguez C, Rodriguez-Sinovas A, Martinez-Gonzalez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect 2008; 21: 218-224.
10. Sanchez-Lozada LG, Tapia E, Johnson RJ, Rodriguez-Iturbe B, Herrera-Acosta J. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl 2003; 86: S9-S14.
11. Zeisberg M, Strutz F, Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000; 13(Suppl 3): S111-S120.
12. Pippal JB, Fuller PJ. Structure-function relationships in the mineralocorticoid receptor. J Mol Endocrinol 2008; 41: 405-413.
13. Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 2005; 19: 2211-2221.
14. Hernandez-Diaz I, Giraldez T, Arnau MR, et al. The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology 2010; 151: 3888-3899.
15. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1235.
16. Stier CT Jr., Rocha R, Chander PN. Effect of aldosterone and MR blockade on the brain and the kidney. Heart Fail Rev 2005; 10: 53-62.
17. Nishiyama A, Abe Y. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006; 100: 9-16.
18. de las Heras N, Ruiz-Ortega M, Miana M, et al. Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 2007; 25: 629-638.
19. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in strokeprone hypertensive rats. Hypertension 1998; 31: 451-458.
20. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836.
21. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 518-533.
22. Kawai T, Masaki T, Doi S, et al. PPAR-γamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; 89: 47-58.
23. Wang W, Liu F, Chen N. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm 2007; 2007: 62641.
24. Sung B, Park S, Yu BP, Chung HY. Amelioration of agerelated inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. Exp Gerontol 2006; 41: 590-599.
25. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003; 307: 854-860.
26. Ohga S, Shikata K, Yozai K, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292: F1141-F1150.
27. Sanz-Rosa D, Cediel E, de las Heras N, et al. Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB/IkappaB system. J Hypertens 2005; 23: 1167-1172.
28. de las Heras N, Ruiz-Ortega M, Ruperez M, et al. Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II. J Renin Angiotensin Aldosterone Syst 2006; 7: 192-200.
29. Martin-Fernandez B, de Las Heras N, Miana M, et al. Structural, functional and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced SGK-1 expression. J Cardiovasc Pharmacol 2011; 57: 114-121.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Methods 2001; 25: 402-408.
31. Sun L, Gao YH, Tian DK, et al. Inflammation of different tissues in spontaneously hypertensive rats. Sheng Li Xue Bao 2006; 58: 318-323.
32. Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol Dial Transplant 2006; 21: 260-263.
33. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T. Saltinduced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007; 50: 877-883.
34. Mezesova L, Bartekova M, Javorkova V, Vlkovicova J, Breier A, Vrbjar N. Effect of quercetin on kinetic properties of renal Na,K-ATPase in normotensive and hypertensive rats. J Physiol Pharmacol 2010; 61: 593-598.
35. Vlkovicova J, Javorkova V, Mezesova L, et al. Dual effect of polyphenolic compounds on cardiac Na+/K+-ATPase during development and persistence of hypertension in rats. Can J Physiol Pharmacol 2009, 87: 1046-1054.
36. Jorgensen PL, Pedersen PA. Structure-function relationships of Na,K, ATP, or Mg binding and energy tranduction in Na,K-ATPase. Biochem Biophys Acta 2001; 1505: 57-74.
37. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
38. Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H. Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increased in PPAR-gamma and decrease in TGF-beta. Int Heart J 2007; 48: 177-186.
39. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261.
40. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus J Clin Endocrinol Metab 2007; 92: 2552-2558.
41. Imanishi T, Ikejima H, Tsujioka H, et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008; 51: 734-741.
42. Jovanovic D, Jovovic D, Mihailovic-Stanojevic N, et al. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 2005; 63: 446-453.
43. Manger WM, Simchon S, Stokes MB, et al. Renal functional, not morphological, abnormalities account for salt sensitivity in Dahl rats. J Hypertens 2009; 27: 587-598.
44. Zhou X, Frohlich ED. Analogy of cardiac and renal complications in essential hypertension and aged SHR or LNAME/ SHR. Med Chem 2007; 3: 61-65.
45. Martinez-Maldonado M, Rodriguez-Sargent C, Cangiano JL, Dworkin LD. Pathogenesis of systemic hypertension and glomerular injury in the spontaneously hypertensive rat. Am J Cardiol 1987; 60: 471-521.
46. Ofstad J, Iversen BM. Glomerular and tubular damage in normotensive and hypertensive rats. Am J Physiol Renal Physiol 2005; 288: F665-F672.
47. Hermida N, Lopez B, Gonzalez A, et al. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 2009; 81: 601-609.
48. Rodriguez C, Alcudia JF, Martinez-Gonzalez J, Raposo B, Navarro MA, Badimon L. Lysyl oxidase (LOX) downregulation by TNF-alpha: a new mechanism underlying TNF-alpha-induced endothelial dysfunction. Atherosclerosis 2008; 196: 558-564.
49. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. Reduced collagen biosynthesis is the hallmark of cerebral aneurysm: contribution of interleukin-1beta and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol 2009; 29: 1080-1086.
50. Xiao H, Zhang YY. Understanding the role of transforming growth factor-beta signalling in the heart: overview of studies using genetic mouse models. Clin Exp Pharmacol Physiol 2008; 35: 335-341.
51. Nonaka TS, Fujita T, Takahashi T, et al. TGF-beta1 and CTGF mRNAs are correlated with urinary protein level in IgA nephropathy. J Nephrol 2008; 21: 53-63.
52. Ruperez M, Ruiz-Ortega M, Esteban V, et al. Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003; 163: 1937-1947.
53. Fan YY, Baba R, Nagai Y, et al. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salttreated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan. Hypertens Res 2006; 29: 169-178.
54. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005; 10: 48-56.